Publications + Presentations

Summary

• President Trump has announced a proposed tariff framework that would impose a 100% tariff on imported generic pharmaceuticals beginning August 1, 2028, and a 200% tariff beginning August 1, 2029.
• Generic pharmaceutical imports would remain tariff-free through August 1, 2028, creating a two-year transition period.
• The proposal is intended to encourage pharmaceutical manufacturers to establish production facilities in the United States.
• Significant uncertainty remains, as no formal tariff order has been issued and key implementation details have not been finalized.
• Global pharmaceutical companies (especially from India, China, and the EU) with significant U.S. market exposure should consider using the transition period to evaluate manufacturing, supply-chain, investment, and market-diversification strategies.

---

Proposed Tariff Framework

President Donald Trump recently announced a proposed tariff framework for imported generic pharmaceuticals that could have significant implications for Indian pharmaceutical manufacturers and other companies serving the U.S. healthcare market.

Under the framework, announced on the President’s Truth Social account, imported generic medicines would remain tariff-free through August 1, 2028. The proposal would then impose a 100% tariff beginning August 1, 2028, followed by a 200% tariff beginning August 1, 2029.

According to the Administration, the objective is to encourage pharmaceutical manufacturers to establish production facilities in the United States. Policies affecting patented and innovative medicines would remain unchanged.

Significant Uncertainty Remains

While the proposed tariff framework reflects a significant policy objective, substantial uncertainty remains regarding its ultimate implementation. No formal tariff order has been issued, key details regarding scope and applicability have not been finalized, and ongoing U.S.-India trade discussions could influence the final outcome.

Businesses should therefore view the announcement as an important indicator of policy direction while continuing to monitor regulatory developments and potential opportunities for negotiated solutions, exemptions, or other modifications.

Strategic Considerations for Indian Pharmaceutical Companies

The announcement also comes amid broader U.S. efforts to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign supply chains. For Indian pharmaceutical companies, the proposal represents less of an immediate disruption and more of a strategic planning challenge.

The United States remains the largest export market for India's pharmaceutical industry, while Indian manufacturers play a critical role in supplying affordable generic medicines to the U.S. healthcare system. At the same time, many leading Indian drugmakers already operate manufacturing facilities in the United States, potentially providing additional flexibility as companies evaluate long-term production and investment strategies.

Planning During the Transition Period

During the proposed transition period, businesses may wish to assess:

• Manufacturing footprints and potential U.S. expansion opportunities
• Supply-chain resilience and sourcing strategies
• Contractual risk allocation and tariff-related provisions
• Exposure to future U.S. tariff measures
• Market diversification and growth opportunities outside the United States
• Ongoing regulatory and trade developments affecting the pharmaceutical sector

Companies with significant U.S. market exposure should also closely monitor regulatory developments and trade discussions that could affect the final shape of any tariff regime.

Looking Ahead

While the proposal reflects a clear policy objective of expanding U.S.-based pharmaceutical manufacturing, the legal, commercial, and healthcare-access considerations involved suggest that further developments are likely before any long-term framework takes effect. The next two years may prove critical for companies evaluating cross-border manufacturing, investment, and market-access strategies.

Kegler Brown's Global Business Practice is monitoring these developments and their potential impact on trade, investment, and supply-chain planning. If you have questions regarding the proposed tariffs or their implications for your business, please contact Vinita Mehra at vmehra@keglerbrown.com.